# NCT03433469 (NCT03433469)

> Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03433469
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University of California, San Francisco
- Conditions: Stage I Non-Small Cell Lung Cancer; Stage IA Non-Small Cell Lung Cancer; Stage IB Non-Small Cell Lung Cancer; Stage II Non-Small Cell Lung Cancer; Stage IIA Non-Small Cell Lung Cancer; Stage IIB Non-Small Cell Lung Cancer; Stage IIIA Non-Small Cell Lung Cancer
- Interventions: Osimertinib; Therapeutic Conventional Surgery
- Enrollment: 27
- Primary outcome: Percentage of Participants With a Major Pathological Response (MPR)

## Indexed commentary on NCT03433469 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 post on Bluesky

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03433469